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Endo~p~da~-24.11 ~~nkephalina~‘, EC 3.4.24.11) from pig kidney hydrolysed neurokinin B at 4 sites: 
As~Met-~is-As~Ph~Ph~V~~ly~~u-Met~* 
The major site of hydrolysis was the Glys-Leu9 bond. Angiotensin converting enzyme (peptidyl dipeptidase 
A, EC 3.4.15.1) from pig kidney hydrolysed substance P releasing the C-terminal tripeptide Gly-Leu- 
MetNH, but failed to hydrolyse neurokinin B. Pig brain striatal synaptic membranes hydrolysed neurokinin 
B producing a similar pattern of products as did endopeptidase-24.11. Substantial inhibition of this activity 
was achieved with the selective inhibitor phosphoramidon. A combination of phosphoramidon and bestatin 
abolished the hydrolysis of neurokinin B by synaptic membranes. Thus, a bestatin-sensitive aminopeptidase 
may play a role in the synaptic metabolism of nenrokinin B in addition to endopeptidase-24.11. This amino- 
peptidase appears to be distinct from aminopeptidase N (EC 3.4.11.2). 
Neuro~~in B ~~opept~e-24.1 I ~~eph~i~e Angiute~in converting enzyme 
Am~opepti~e 
1. INTRODUCTION 
Neurokinin B (neuromedin K) is a recently 
discovered peptide present in mammalian CNS, 
where it may function as a neurotransmitter [l]. 
The peptide shares a common C-terminal se- 
quence, Phe-Xaa-Gly-Leu-MetNHt, with the 
tachykinin family of peptides which include 
substance P [2]. The synaptic inactivation of 
substance P has been extensively investigated and 
at least 2 major cell surface peptidases have been 
implicated in its hydrolysis: endopeptidase-24.11 
(‘enkephalinase’, EC 3.4.24.11) and angiotensin 
converting enzyme (peptidyl dipeptidase A, EC 
3.4.15.1) (review [3]). Synaptic membranes 
prepared from pig or human striatum hydrolyse 
substance P at the same sites as does 
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endopeptidase-24.11 and this hydrolysis is in- 
hibited by the selective inhibitor phosphoramidon 
and by a specific antiserum to the enzyme [4,.5]. On 
the basis of such evidence we have concluded that 
endopeptidase-24.11 may play a significant role in 
the synaptic metabolism of substance P as well as 
enkephalins and certain other neuropeptides [4,6]. 
However, inhibitors of angiotensin converting en- 
zyme such as captopril have also been shown to 
potentiate certain of the peripheral actions of 
substance P [7] suggesting that this enzyme might 
play a role in substance P metabolism in vivo, at 
least in peripheral tissues. 
The metabolism of neurokinin B has not 
previously been reported. Here we show that pig 
striatal synaptic membranes and purified prepara- 
tions of endopeptidase-24.11 hydrolyse neurokinin 
B in an identical fashion. Angiotensin converting 
enzyme purified from pig kidney appears unable to 
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hydrolyse neurokinin 3. We therefore conchrude 
that, of identified cell-surface peptidases, onfy 
endopeptid~e-24-11 has the general capacity to 
hydrolyse and inactivate tachykinin peptides, 
2. EXPERIMENTAL 
2.1. Peptides and inhibitors 
Neurokinin B was a gift from Merck, Sharp & 
Dohme Research Laboratories, Harlow, England, 
and its purity was checked by reverse phase HPLC. 
Captopril (SQ14225, D-3-mercapta-2-methyl- 
pro~~oyl-L-proline~ was a gift from the Squibb 
Institute for Medical Research, Princeton, NJ. 
Lisinopril ~~-~~~-l-~bo~-3-phe~ylpropyl]-L- 
Iysyl-L-proline, MKS21) was a gift from Dr A.A. 
Patchett, Merck, Sharp and Dohme Research 
Laboratories, Rahway, N.I- Bestatin was pur- 
chased from Sigma. Other chemicals were from 
sources previously noted [4-61. 
2.2. Membranes and enzyme preparations 
Crude synaptosomab’mitochondrial (P2) prepa- 
rations and synaptic membranes from pig striatum 
were prepared as in [4]. Endopeptidase-24.11 was 
purified from pig kidneys, the richest source of the 
enzyme> by immunoaf~~ty chromatography [gf* 
Likewise angiotensin converting enzyme was 
purified from pig kidneys by affinity chro- 
matography using Lisinopril-Sepharose {9]. Both 
enzymes were apparently homogeneous by SDS- 
polya~rylamide gel ele~trophoresis. 
Samples of synaptic membranes (29Ogg pro- 
tein), endopeptidase-24.11 (200 ng) or angiotensin 
converting enzyme (100 ng) were incubated with 
0.5 mM neurokinin B for various times at 37°C 
(final volume 100 al). The reaction was stopped 
and the products analysed by HPLC as described 
for substance P [4]. Products were identified either 
by using marker peptides or by collection of the in- 
dividual product peaks and amino acid analysis of 
the ~o~espo~ding peptides [4], 
3. RESULTS 
3.1. Hydrolysis of neurokiPrin B by pig kidney 
endopeptidase-24. I I 
Neurokinin B was hydrolysed by endopeptidase- 
24.11 and 7 peptide products were identified (table 
l), The identity of these peaks was confirmed by 
amino acid analysis and, in the case of Val-Gly, by 
the use of a marker peptide. The identified pro- 
ducts could be attributed to hydroIysis at 4 sites: 
4 t i 1 
Asp-Met-His”Asp-Phe-Phe-Val-sly-Leu-MetNHz 
Table 1 
Products released by incubation of neurokinin B with 
endopeptidase-24.11 
Peak Retention Peptide identified Fragment of 
no. time (mm) neurokinin B 
1 2.10 V-G 7- 8 
2 2.32 D-M-H-D l- 4 
3 3.42 L-Ma 9-10 
4 4.84 F-V-G 6- 8 
5 7.64 D-M-H-D-F I- 5 
6 9.76 F-F s- 6 
7 10.42 F-F-V-G S- 8 
8 12.64 D-M-H-D-F-F-V-G l- 8 
9 17.46 D-M-H-D-F-F-V-G-L-Ma neurokinin B 
Data are from incubations achieving >SOYo degradation of 
neurokinin 3, The identity of peak 1 was confirmed by co-efution 
with the authentic peptide. The other products were confirmed by 
amino acid analysis 
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The effect of inhibitors on the hydrolysis of neurokinin B by pig striatal synaptic membranes 
Peak Peptide Effect of inhibitors on peak area 
(contro1 (no inhibition) = 100 for each peak) 
Phosphor- Bestatin Captopril P + B C+B P+C+B 
amidon (P) (B) (C) 
1 V-G 48 66 98 0 8 0 
2 D-M-H-D 0 108 76 0 50 0 
3 L-Ma 11 67 75 11 67 0 
4 F-V-G 0 224 122 0 237 0 
5 D-M-H-D-F 0 78 95 0 84 0 
6 F-F 0 0 0 0 0 
7 F-F-V-G 52 : 105 b b b 
8 D-M-H-D-F-F-V-G 10 93 89 14 104 11 
The inhibitors were added at the start of the incubation period. Concentrations: 
phosphoramidon, 1 gM; bestatin, 100 PM; captopril, 1 pM. In the absence of any inhibitors, 
approx. 50% of the substrate was hydrolysed under the conditions used. a, peak 6 was not 
detectable in the absence of any inhibitors due to rapid hydrolysis by endogenous 
aminopeptidases. It was only detectable when bestatin was included. b, peak 7 and bestatin 
elute with very similar retention times so an estimate of inhibition was not possible in these 
The most rapidly hydrolysed site was the 
Gly’-Leu’ bond releasing Leu-MetNHz, as is the 
case for substance P (41. Hydrolysis of the 
Phe6-Val’ bond was a relatively minor cleavage. 
3.2. Neurokinin B is not hydrolysed by pig kidney 
angiotensin converting enzyme 
Angiotensin converting enzyme hydrolyses 
substance P with release of the C-terminal tripep- 
tide Gly-Leu-MetNH2 [7,10,11]. Neurokinin B 
(0.5 mM) was incubated with a purified prepara- 
tion of angiotensin converting enzyme at 37OC for 
periods of time up to 18 h at 37°C. No Gly-Leu- 
MetNHz was formed under these conditions nor 
was any other product detectable. Fu~hermore, 
there was no significant loss of substrate during the 
incubation. Under identical conditions substance P
was hydrolysed as reported [7,10,1 l] and this 
hydrolysis was prevented by the selective inhibitor 
captopril (1 pM). 
3.3. Hydrolysis of neurokinin B by synaptic- 
membrane preparations from pig striatum 
Neurokinin B was hydrolysed by synaptic- 
membrane preparations. In some experiments 
selective peptidase inhibitors were included in the 
incubation mixture. The results are summarised in 
table 2. The pattern of products formed was 
similar to that observed when neurokinin B was in- 
cubated with endopeptidase-24.11. Substantial in- 
hibition of the formation of most products was 
observed when phosphoramidon (1 PM) was in- 
cluded. Virtually complete inhibition of 
neurokinin B hydrolysis was achieved when a com- 
bination of phosphoramidon (1 PM) and the 
aminopeptidase inhibitor bestatin (0.1 mM) was 
included. Captopril (1 PM) had little effect, 
Similar results were obtained with a crude synap- 
tosom~/mitochondrial (Pz) preparation sug- 
gesting that certain peptidases had not been selec- 
tively removed during the purification of synaptic 
membranes. 
4. DISCUSSION 
4.1. Specificity of endopeptidase-24. I1 and 
angiotensin converting enzyme 
Four bonds in neurokinin B were hydrolysed by 
endopeptidase-24.11. All the sites of hydrolysis are 
consistent with the previously reported specificity 
of the enzyme [6]. In all cases hydrolysis occurred 
at bonds involving the amino groups of 
13s 
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hydrophobic residues. The major cleavage point 
involved the Gly*-Leu’ bond releasing Leu- 
MetNHz. Hydrolysis at this site would destroy the 
biological activity of neurokinin B which resides in 
the C-terminal portion of the peptide. 
The previous report by a number of groups 
[7,10,1 l] that substance P could be hydrolysed by 
angiotensin converting enzyme releasing a C- 
terminal tripeptide was somewhat unexpected. 
Substance P is amidated at the C-terminus and 
angiotensin converting enzyme has been regarded 
as a peptidyl dipeptidase releasing dipeptides from 
an unblocked C-terminus [12]. Our preparation of 
angiotensin converting enzyme could also 
hydrolyse substance P in agreement with the 
previous reports [7,10,1 I]. Despite the similarity in 
C-terminus between neurokinin B and substance 
P, no hydrolysis of the former peptide could be 
observed with angiotensin converting enzyme from 
pig kidney. We therefore conclude that neurokinin 
B is a substrate for endopeptidase-24.11 but not 
for angiotensin converting enzyme. The precise 
structural features that can allow angiotensin con- 
verting enzyme to function as an endopeptidase 
with certain substrates will require further evalua- 
tion with model peptides. Of the 2 well- 
characterised cell-surface peptidases it would ap- 
pear that only endopeptidase-24.11 has a general 
capacity to hydrolyse and inactivate tachykinins. 
4.2. Hydrolysis of neurokinin B by pig striatal 
synaptic membranes 
Phosphoramidon is a specific inhibitor of 
endopeptidase-24.11 [ 3 1. Our results show that 
substantial inhibition of neurokinin B hydrolysis 
by synaptic membranes or with a crude synap- 
tosomal (Pz) membrane preparation is achieved 
with phosphoramidon alone. Captopril had little 
effect. A combination of phosphoramidon and 
bestatin completely blocked the hydrolysis of 
neurokinin B as is the case for the hydrolysis of 
cholecystokinin-8 by syhaptic membranes [ 141. 
Thus, a bestatin-sensitive peptidase may also play 
a role in neurokinin B hydrolysis, although the en- 
dopeptidase appears to be the predominant activi- 
ty. Aminopeptidase N (EC 3.4.11.2) is present in 
synaptic membranes [15] and is sensitive to 
bestatin. However, a purified preparation of 
aminopeptidase N failed to hydrolyse neurokinin B 
(unpublished observations). Both cholecystoki- 
nin-8 and neurokinin B possess an N-terminal 
aspartyl residue and may therefore be susceptible 
to the action of aminopeptidase A (EC 3.4.11.7) 
which is sensitive to bestatin and shows a pref- 
erence for acidic residues. However, the presence 
of this enzyme has yet to be confirmed in synaptic 
membrane preparations. 
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